Search results
29 lip 2020 · Finally, multivalent approaches such as those discussed in this commentary, where heterologous Salmonella antigens are simultaneously expressed in a single vaccine platform, offer a practical and cost-effective strategy for targeting co-endemic serovars.
With other new vaccines under investigation, including live-attenuated, protein-based and GMMA vaccines, now is an exciting time for the Salmonella vaccine field. Keywords: vaccines, Salmonella, nontyphoidal, typhoid, enteric, global health, glycoconjugate, GMMA. Protection Against more than Diarrhea
7 maj 2014 · The combination of high yield and a simple production process makes this a highly-affordable technology, particularly suited for the development of vaccines for low- and middle-income countries, where cost-of-goods is a key consideration. 65 As the reactogenicity relative to the immunogenicity of GMMA vaccines in man is currently unknown ...
New glycoconjugate vaccines against S. Typhi are becoming available with similar vaccines against other invasive serovars in development. With other new vaccines under investigation, including live-attenuated, protein-based and GMMA vaccines, now is an exciting time for the Salmonella vaccine field.
7 maj 2014 · After years of lack of investment in new Salmonella vaccines, recent times have seen increased interest in the area led by emerging-market manufacturers, global health vaccine institutes and academic partners. New glycoconjugate vaccines against S. Typhi are becoming available with similar vaccines against other invasive serovars in development.
There are currently three vaccines licensed for use in humans, all targeting typhoidal Salmonella: the live attenuated oral vaccine S. Typhi Ty21a, Vi capsule polysaccharide vaccine, and Vi polysaccharide conjugated with tetanus toxoid ( 11 – 14 ).
2 cze 2023 · While a trivalent typhoid/nontyphoidal Salmonella vaccine is attractive for Africa, and a bivalent enteric fever vaccine for Asia, a quadrivalent vaccine covering the 4 main disease-causing serovars of Salmonella enterica would provide a single vaccine option for global Salmonella coverage.
